Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study

Br J Haematol. 2014 Nov;167(3):423-6. doi: 10.1111/bjh.12987. Epub 2014 Jun 30.
No abstract available

Keywords: heart; iron chelation; iron overload; magnetic resonance imaging.

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Benzoates / administration & dosage
  • Benzoates / therapeutic use*
  • Cardiomyopathies / drug therapy*
  • Cardiomyopathies / etiology
  • Cardiomyopathies / pathology
  • Chelation Therapy*
  • Deferasirox
  • Female
  • Ferritins / blood
  • Hemosiderosis / drug therapy*
  • Hemosiderosis / etiology
  • Hemosiderosis / pathology
  • Humans
  • Iron Chelating Agents / administration & dosage
  • Iron Chelating Agents / therapeutic use*
  • Liver / pathology
  • Magnetic Resonance Imaging
  • Male
  • Medication Adherence
  • Prospective Studies
  • Stroke Volume
  • Transfusion Reaction
  • Triazoles / administration & dosage
  • Triazoles / therapeutic use*
  • Young Adult
  • beta-Thalassemia / complications*
  • beta-Thalassemia / therapy

Substances

  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Ferritins
  • Deferasirox